SYDNEY, July 3, 2026 /PRNewswire/ -- Global travel service provider Trip.com has today unveiled its upcoming Jet Set July Mega Sale. Tailored exclusively for Australian holidaymakers, the initiative features a massive inventory of premium coupons, flash sales, and value drops across flights, accommodations, global attractions, transports and eSIMs from 7 to 12 July.
High-Flying Flight Deals & Unmissable Flash Fares
For Australian travellers with wanderlust, Trip.com is unlocking unbeatable flight deals and flash sales—your dream trip is now more affordable than ever.
- Mega Promo Codes:50% off flight codes (capped at $100) and 25% off flight codes (capped at $50).
- Domestic & Trans-Tasman Savings:Up to $40 off domestic and Australia-New Zealand flight promo codes with Jetstar, Virgin Australia and Qantas.
- Airline Exclusive Offers:Up to $100 off airline exclusive promo codes, alongside special airline exclusive fares.
- $29 Domestic Flash Sale:One-way domestic flights from just $29 to and from Sydney, Melbourne, Brisbane, Adelaide and Gold Coast.
- International Flash Sales:One-way fares from $109 to Bali from Sydney, Melbourne, Brisbane or Perth; from $149 to Ho Chi Minh City from Sydney, Melbourne, or Brisbane; and from $189 from Sydney to Shanghai.
- Bundle Savings: An extra 10% off flight and hotel packages via dedicated codes (capped at $50).
Hotel, Attraction and Destination Savings
Beyond the skies, the sale provides end-to-end booking promotion to completely transform the ground experience:
- Accommodation Discounts:50% off promo codes (capped at $100) and 25% off codes (capped at $50), along with 15% off codes across Australia, New Zealand and Asia. Premium bookers can also leverage exclusive global hotel deals scaling up to 70% off.
- Hotel Flash Sale:Up to 89% off selected properties in Japan and Thailand.
- Attraction and Tours: Buy 1 Get 1 Free passes in Universal Studio Japan, 50% off Shanghai Disneyland entry, and exclusive global experiential rates.
- Seamless Connectivity: Stay connected globally via 50% off eSIM codes, alongside $1 eSIM flash sale.
- Ground Transportation and Cruising: Up to 50% off car hire, up to 20% off airport transfer, up to 50% off train rides in mainland China, Hong Kong, Europe, Japan and Korea, plus up to $150 off cruises (minimum spend applies).
Bonus Winter Savings: Active Concurrent Campaigns
To maximise winter savings, travellers can also access two running partner campaigns:
- "This is China" (On now through 27 July): Up to $100 off flights departing Sydney to China, with fresh code drops releasing every Tuesday at 2pm AEST. Special $189 one-way flash sales drop on 7 July (Sydney to Shanghai) and 21 July (Sydney to Beijing).
- "Fly with China Eastern" (On now through 17 July): In partnership with China Eastern Airlines, Aussie travellers can snag up to $100 off flights departing Australia to different destinations (flights from Sydney to China excluded).
Terms and Conditions apply. All promotional offers are available on a first-come, first-served basis within the specified period and while stocks last. Please note that all deals are in AEST time.
For more information, please visit https://au.trip.com/.
About Trip.com
Trip.com is an international one-stop travel service provider, available in 27 languages across 48 countries and regions in 44 local currencies. Offering an extensive hotel and flight network of more than 1.7 million hotels and flights from over 680 airlines, along with over 350,000 in-destination activities, Trip.com covers 3,500 airports in 220 countries and regions. Trip.com's world-class 24/7 multilingual customer service helps to 'create the best travel experience' for its millions of customers worldwide. To book your next trip, visit Trip.com.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Australia, Get Ready for Jet Set: Trip.com Slashes Flights, Hotels, and eSIMs in Major July Sale
Late-breaking HRX data advance Field Medical's "instantaneous ablation" workflow and expand the clinical evidence for high-voltage focal PFA with the FieldForce™ PFA System
ATLANTA and CARLSBAD, Calif., Sept. 20, 2026 /PRNewswire/ -- Field Medical, Inc., advancing high-voltage focal pulsed field ablation (PFA) for complex arrhythmias, today announced publication of 12-month results from the first-in-human Field PULSE trial in JACC: Clinical Electrophysiology. The findings were presented simultaneously as a Late-Breaking Clinical Trial at HRX Live 2026.
Field Medical developed the FieldForce™ PFA System around a high-voltage focal PFA architecture designed first for the ventricle, where depth, stability and control are among the most difficult challenges in ablation. Field PULSE extends that work into the atrium and evaluates a subsecond point-by-point workflow Field Medical terms "instantaneous ablation." In this study, the approach was associated with procedural efficiency, durable pulmonary vein isolation (PVI) and flexibility beyond the pulmonary veins, without the need for prolonged catheter stability.
Key Findings:
- Procedural efficiency with subsecond focal PFA: 13-minute median elapsed PVI ablation time, with a fastest time of 7.7 minutes
- Durable PVI with the optimized waveform: 94.2% per-vein durability reflecting progressive improvement with waveform evolution
- Flexible focal ablation: 49% of patients received non-PV ablation for additional atrial targets
- No primary safety events were observed
- 80% freedom from atrial arrhythmias at 12 months with the optimized waveform
"Field PULSE demonstrates the feasibility of truly instantaneous focal PFA," said Vivek Reddy, M.D., co-principal investigator, lead author and electrophysiologist at Mount Sinai Health System. "Delivering the full application in less than 200 milliseconds reduces the need for prolonged catheter stability while preserving the flexibility of point-by-point ablation. The procedural efficiency, safety and pulmonary vein durability observed with the optimized waveform support continued clinical development of this approach."
The publication builds on Field Medical's peer-reviewed clinical work in ventricular tachycardia. Six-month outcomes from the company's first-in-human VCAS trial were published in Circulation in 2025. Field PULSE now adds first-in-human, peer-reviewed atrial data evaluating the same high-voltage focal PFA architecture through a distinct focal workflow in a different cardiac substrate.
"We designed FieldForce to solve some of the hardest problems in focal cardiac ablation, beginning in the ventricle," said Mark A. Turco, M.D., president and chief executive officer of Field Medical. "Field PULSE demonstrates that the same high-voltage focal PFA architecture can support an 'instantaneous ablation' workflow in the atrium. This growing body of evidence reinforces the range of the platform: depth and focal control in the ventricle, speed and precision in the atrium, and the versatility to address very different cardiac substrates through a familiar point-by-point approach. These results add important clinical evidence as we continue to advance our differentiated PFA platform."
The study, "High-Voltage Focal PFA Catheter for 'Instant' Point-By-Point Ablation: The First-In-Human FIELD-PULSE Trial to Treat AF," was published online in JACC: Clinical Electrophysiology concurrent with the HRX presentation. DOI: 10.1016/j.jacep.2026.09.001.
About Field Medical®, Inc.
Field Medical is a clinical-stage medical technology company committed to advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias. The company was founded by Steven Mickelsen, M.D., CTO, a pioneer and global thought leader in PFA whose work has helped shape the evolution of the field. The FieldForce PFA System integrates a focal catheter design with proprietary FieldBending™ energy designed to safely deliver efficient, precise ablation with the goal of improving outcomes in ventricular and atrial arrhythmia treatment. In 2024, Field Medical earned Breakthrough Device Designation and gained entry into the FDA TAP Pilot Program for its ventricular tachycardia indication. In October 2025, the VCAS trial was published in Circulation.
For more information, visit fieldmedicalinc.com and follow us on LinkedIn and YouTube.
The FieldForce™ PFA System is an investigational device and is limited by federal (or United States) law to investigational use.
Media Contact
Holly Windler
619.929.1275
media@fieldmedicalinc.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
JACC: Clinical Electrophysiology Publishes 12-Month Outcomes from Field Medical's First-in-Human Field PULSE Trial: 94.2% Per-Vein PVI Durability with Optimized Waveform
